Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of
34,541,064 shares with preferential rights for the Company's existing shareholders, which was
resolved upon by the board of directors on the 25 September 2019, pursuant to the authorization
from the extra general meeting on 16 August 2019 (the "Rights Issue"). Acarix today announce
the final outcome of the Rights Issue.
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, email@example.com) is Certified Advisor of Acarix.